Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Trajectory of cognitive functions in bipolar disorder: for better or worse?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Incidence of suicidal behaviour and violent crime following antidepressant medication: a Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Response to comment on Osler et al: misinterpretation of pre- and post differences invalidate the authors' conclusion

    Research output: Contribution to journalComment/debateResearchpeer-review

  4. Societal costs of Borderline Personality Disorders: a matched-controlled nationwide study of patients and spouses

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Meta-analysis of antidepressant effects of anti-inflammatory drugs-reply

    Research output: Contribution to journalComment/debateResearchpeer-review

  1. Reappraisal is an effective emotion regulation strategy in children with Tourette syndrome and ADHD

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dr. Uhre et al. Reply

    Research output: Contribution to journalLetterResearchpeer-review

  • B Galling
  • J A Vernon
  • A K Pagsberg
  • A Wadhwa
  • E Grudnikoff
  • A J Seidman
  • M Tsoy-Podosenin
  • M Poyurovsky
  • J M Kane
  • C U Correll
View graph of relations

OBJECTIVE: To evaluate the efficacy and safety of antidepressant augmentation of antipsychotics in schizophrenia.

METHODS: Systematic literature search (PubMed/MEDLINE/PsycINFO/Cochrane Library) from database inception until 10/10/2017 for randomized, double-blind, efficacy-focused trials comparing adjunctive antidepressants vs. placebo in schizophrenia.

RESULTS: In a random-effects meta-analysis (studies = 42, n = 1934, duration = 10.1 ± 8.1 weeks), antidepressant augmentation outperformed placebo regarding total symptom reduction [standardized mean difference (SMD) = -0.37, 95% confidence interval (CI) = -0.57 to -0.17, P < 0.001], driven by negative (SMD = -0.25, 95% CI = -0.44-0.06, P = 0.010), but not positive (P = 0.190) or general (P = 0.089) symptom reduction. Superiority regarding negative symptoms was confirmed in studies augmenting first-generation antipsychotics (FGAs) (SMD = -0.42, 95% CI = -0.77, -0.07, P = 0.019), but not second-generation antipsychotics (P = 0.144). Uniquely, superiority in total symptom reduction by NaSSAs (SMD = -0.71, 95% CI = -1.21, -0.20, P = 0.006) was not driven by negative (P = 0.438), but by positive symptom reduction (SMD = -0.43, 95% CI = -0.77, -0.09, P = 0.012). Antidepressants did not improve depressive symptoms more than placebo (P = 0.185). Except for more dry mouth [risk ratio (RR) = 1.57, 95% CI = 1.04-2.36, P = 0.03], antidepressant augmentation was not associated with more adverse events or all-cause/specific-cause discontinuation.

CONCLUSIONS: For schizophrenia patients on stable antipsychotic treatment, adjunctive antidepressants are effective for total and particularly negative symptom reduction. However, effects are small-to-medium, differ across antidepressants, and negative symptom improvement seems restricted to the augmentation of FGAs.

Original languageEnglish
JournalActa Psychiatrica Scandinavica
Volume137
Issue number3
Pages (from-to)187-205
Number of pages19
ISSN0001-690X
DOIs
Publication statusPublished - Mar 2018

    Research areas

  • Journal Article

ID: 52736217